Novavax Shares Pop 6% on Preclinical Influenza Nanoparticle Data
Novavax, Inc. (NASDAQ:NVAX) shares were rising 5% in after-hours trading yesterday after the company reported second-quarter financials and provided investors with an update …
Novavax, Inc. (NASDAQ:NVAX) announced its financial results for the second quarter and six months ended June 30, 2017.
Novavax, Inc. (NASDAQ:NVAX) investors are scratching their heads and trying to figure out whether this morning’s drop has created an attractive entry point.
Novavax, Inc. (NASDAQ:NVAX) announced positive topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults, …
Novavax, Inc. (NASDAQ:NVAX) announced its financial results for the first quarter ended March 31, 2017.
Novavax, Inc. (NASDAQ:NVAX) shares fell almost 10% in after-market hours on the heels of the firm’s release of fourth-quarter financials and clinical updates.
Novavax, Inc. (NASDAQ:NVAX) announced its financial results for the fourth quarter and twelve months ended December 31, 2016.
FBR analyst Vernon Bernardino met with Novavax, Inc. (NASDAQ:NVAX) management last week to discuss fundamentals and future 2017 clinical development.
Novavax, Inc. (NASDAQ:NVAX) announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F …
